Cassie is on the growth equity team focusing on software investments. She is passionate about finding and supporting best-in-class software companies and enjoys working with founders and management teams to build sustainable growth.

She began her career in M&A investment banking as an analyst at Bowstring Advisors (acquired by Citizens Equity Group) in their software and technology group. She later spent two years with District Capital Partners as an associate, focusing on executing M&A roll-up strategies for private-equity-backed software companies. Most recently, she was an associate at Luminate Capital Partners, a private equity firm that focuses on majority buyouts of growth-oriented software firms in San Francisco.

Cassie graduated from Washington and Lee University where she double majored in Finance and French.

Umang focuses on early-stage and growth equity investments in Indian companies across a wide range of sectors.

Prior to joining Norwest, Umang was part of Mirae Asset’s Venture Capital (global growth equity fund with an AUM of ~$3bn) where he worked across sectors such as Enterprise Software, Logistics and Fintech. Prior to Mirae, he worked as an Associate at EY and Deutsche Bank’s Technology Investment Banking team, where advised businesses in the Enterprise Software and Fintech verticals.

Umang is a qualified Chartered Accountant and a CFA Level 3 candidate. He holds a Bachelors of Commerce degree from N.M College, Mumbai.

Irem brings over a decade of investing and operating experience across various stages of healthcare services and healthcare technology companies. At Norwest, she focuses on venture and growth equity opportunities across healthcare services, healthcare IT, pharma services and digital health.

Prior to joining Norwest, Irem worked at Summit Partners where she focused on healthcare growth stage businesses and was a board member or observer for four companies across risk-based providers and healthcare tech-enabled services. She was also a Principal at McKesson Ventures where she led investments in value-based care and pharma IT/services. Irem helped source or served as a board observer for Landmark Health (acquired by Optum), Aledade, IVX Health (recapped by Great Hill Partners), OncoHealth (formerly Oncology Analytics), SHYFT Analytics (acquired by Medidata), Aetion, Curana Health (formerly AllyAlign), Komodo Health, Kyruus and Evariant (acquired by Healthgrades).

Prior to joining McKesson, Irem was part of the founding team of Burd Health where she led the development and implementation of value-based initiatives for self-insured organizations across network management, pharmacy benefit management, and wellness products. She also served in product and business development roles with healthcare startups Omada Health and Caremerge (acquired by VoiceFriend) and was an intern at Andreessen Horowitz where she sourced digital health investments.

Irem started her career as an investment associate at Madison Dearborn Partners and an investment banking analyst in the Healthcare Group at Bank of America Merrill Lynch where she analyzed mergers and acquisitions for companies across life sciences, medical devices and healthcare services.

Irem holds a BS in biomedical engineering and economics, magna cum laude, from Duke University and an MBA from the Stanford Graduate School of Business, where she was an Arbuckle Leadership Fellow and Co-President of the Healthcare Club.

Dr. Zack Scott previously served on the board of directors for Cianna Medical, Coherex Medical, Evidation Health, Providence Medical Technology, Respicardia, Spiration, and Syapse.

Prior to joining Norwest, Zack was the co-founder and managing partner of Revelation Partners, a dedicated secondary investor specializing in shareholder liquidity and growth capital for healthcare companies. During his time at Revelation Partners, he made notable investments in Omada Health, iRhythm Technologies (IPO), SetPoint Medical, and Respicardia (acquired by Zoll Medical).

Before working in private equity, Zack was a General Surgery resident at Oregon Health & Science University in Portland, Oregon. He earned his M.D. from the University of Texas Health Science Center at San Antonio where he was a member of the AOA Medical Honors Society, and subsequently earned an M.B.A. with a specialized certificate in Health Sector Management from The Fuqua School of Business at Duke University where he was a Fuqua Scholar.

Brian is an experienced life sciences investor who focuses on early to mid-stage companies.

Prior to joining Norwest, Brian worked at Blackstone Life Sciences, where he helped lead over $1.5B of investments across biotech, medical devices, and diagnostics. He was a Board Observer or Alliance Committee Member at 5 companies, working closely with management teams on clinical trials, FDA approval process, and commercial strategy. Brian was previously an Engagement Manager at McKinsey & Company, where he advised companies across the healthcare industry.

Brian has a medical degree from Stanford and MBA from Harvard. His research on prostate cancer, diabetic macular edema, and patient safety has been published in multiple peer-review journals.

Krina focuses on growth equity investments across a wide range of sectors including consumer, internet, business services and technology.

Prior to joining Norwest, Krina worked at Credit Suisse as an Investment Banking Analyst in the New York Healthcare Group.

Krina holds a bachelor of science in business with a concentration in finance and a minor in public policy & management from New York University, Leonard N. Stern School of Business.

Ehi focuses on venture opportunities in the healthcare sector, including therapeutics, medical devices, diagnostics, digital health and health tech IT and services.

Ehi was previously at McKinsey & Company’s Life Sciences practice, where he advised clients in the pharmaceutical and medical products industries on corporate strategy, M&A and R&D.

Ehi has an MD and a PhD from the MSTP at Washington University School of Medicine. During his PhD, he published papers on the genetic mechanisms of risk in congenital heart disease. He also has bachelor’s degrees in Biology and Chemistry from Emory University, where he graduated with highest honors.

Joe focuses on growth equity investments in healthcare, including healthcare services, pharma services, healthcare IT, medical devices, and digital health.

Joe joins Norwest from Evercore in New York, where he worked as a senior associate on the Healthcare Services & Technology Equity Research team.

Joe graduated from Georgetown University as a George F. Baker Scholar with a bachelor’s degree in Government and History.

John is a member of Norwest’s growth equity team where he is focused on enterprise software and tech-enabled services companies.

Prior to joining Norwest, John was a Principal at Spring Mountain Capital where he helped lead investments across a variety of enterprise software and digital health companies including (acquired by Press Ganey), Prevalent (recapped by Insight Partners), Koneksa, Splash, Keen Decision Systems and EverWash. Prior to that, he was a Growth Equity Analyst at HealthCor Partners where he was involved in companies in the healthcare sector including Natera (IPO: NTRA), Corindus (acquired by Siemens) and HeartFlow.

John graduated from Carnegie Mellon University with a Masters and a Bachelor of Science in electrical and computer engineering. He also holds a Bachelor of Science in economics.

Michael focuses on growth equity investments across a wide range of sectors including technology, business services, internet and consumer.

Prior to joining Norwest full-time, Michael was a growth equity intern where he researched and presented investment opportunities.

Michael received a B.A. in economics from Harvard College, where he was a three-time captain of the varsity swim team.